Citius Pharma (CTXR): Price-to-Revenue Ratio

Brandmark of citiuspharma.com (CTXR)

Citius Pharmaceuticals operates amidst intense patent battles where the failure of key trials could undermine stability. The biopharmaceutical business relies on an ethical approach and the recruitment of top scientists to develop breakthrough medicines. Demand for intensive care treatments is rising, driven by the hospital sector. The price-to-sales ratio reflects the valuation dynamics, with the 2.10 level serving as a critical benchmark.

CTXR Citius Pharmaceuticals, Inc. P/S Multiple (02/14/2026 - 11/13/2026)

Citius Pharmaceuticals (CTXR) - metric breakdowns and financial figures

- current quotes and average value forecast:
Market Price citiuspharma.com|CTXR - Price Target Chart
- stock exchange capitalization data:
Market Value Citius Pharma|CTXR - Total Company Value
- issuer book value statistics:
Net Asset Value per Share Citius Pharmaceuticals|CTXR - Book Capitalization|Market Value to Equity Ratio citiuspharma.com|CTXR - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
Debt to Capital Citius Pharmaceuticals|CTXR - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital citiuspharma.com|CTXR - Company Total Debt|Debt to Book Capital Citius Pharma|CTXR - Company Long-Term Debts|Company Short-Term Loans and Borrowings Citius Pharmaceuticals|Immediate Liquidity citiuspharma.com
- earnings and multiples data:
CTXR - Company Net Income|Expected Net Income Citius Pharmaceuticals|CTXR - P/E Multiple|Forward P/E Multiple citiuspharma.com|CTXR - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Citius Pharma|CTXR - Operating profit before deduction of amortization|Net earnings per one share for the last twelve months Citius Pharmaceuticals|CTXR - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months citiuspharma.com|CTXR - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Citius Pharmaceuticals
- issuer revenue and sales details:
CTXR - Company Sales|Company Projected Revenue Volume citiuspharma.com|CTXR - P/S Multiple|Market Cap to Expected Sales Ratio Citius Pharma
Summary company analytics:Citius Pharmaceuticals Inc.
Mass-produced product of Citius Pharmaceuticals, Inc.

Professional asset selection requires separating market noise from fundamental value. The P/S ratio compares the market capitalization of Citius Pharmaceuticals (CTXR) with its actual sales volume, determining the cost of each dollar of revenue. Amid geopolitical risks and raw material supply disruptions, this metric reveals the real resilience of the business. Historical P/S dynamics allow for an assessment of the premium paid for the company given current operational threats.

Competing companies

INCY - Price to Sales|Price-to-Revenue Ratio HUTCHMED HCM|Nuvation Bio Inc - Price-to-Revenue Ratio|DAWN - Price-to-Revenue Ratio|Price to Sales Monopar Corp|INBX: P/S Multiple|Price-to-Revenue Multiple I-Mab Biopharma IMAB|Market Cap to Revenue FENC|Price to Sales Heron Therapeutics Inc HRTX|Market Cap to Revenue NVCT (Nuvectis)|CHRS (Coherus BioSciences, Inc) - Market Capitalization-to-Revenue Ratio|Corbus Pharmaceuticals - Market Cap to Revenue|Market Cap to Sales Volume CRDF (Cardiff Oncology Inc.)|BeyondSpring - P/S Multiple|Market Capitalization-to-Revenue Ratio BCAB (BioAtla, Inc.)|LIXT: P/S Multiple|Price to Sales Cellectar Corp (CLRB)|Price-to-Revenue Ratio BioLineRx Ltd.|CANF: Market Capitalization-to-Revenue Ratio|P/S Multiple APRE|P/S Multiple kaziatherapeutics.com (KZIA)|Price-to-Revenue Ratio Silexion Therapeutics SLXN|NCNA (NuCana PLC) - Price-to-Sales Ratio|CMRX: Market Cap to Revenue|Price to Sales cyclacel.com|GTHX: P/S Multiple|Market Cap to Revenue Kronos Bio Inc|KTRA (Kintara) - P/S Multiple|Oncternal Corp (ONCT) - Price-to-Revenue Coefficient|Market Cap to Revenue PRTG (Portage Biotech Inc.)